Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCC4001 + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Artiva Biotherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GCC4001 + obinutuzumab is a combination therapy consisting of allogeneic cord blood-derived naive natural killer (NK) cells (GCC4001, also known as AB-101) and the humanized glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab. Developed by GC Cell (a subsidiary of GC Biopharma) and its partner Artiva Biotherapeutics, this therapeutic approach is designed to treat B-cell mediated autoimmune diseases, primarily systemic lupus erythematosus (SLE). The mechanism of action relies on the synergistic effect of the NK cells and the antibody; obinutuzumab binds to CD20-positive B cells, while the allogeneic NK cells provide a potent effector population to enhance antibody-dependent cellular cytotoxicity (ADCC), leading to more efficient depletion of pathogenic B cells compared to antibody monotherapy. The program has received Investigational New Drug (IND) clearance from the US FDA for clinical evaluation in SLE.
- Brand names
- Gazyva
- Other names
- AB-101 + obinutuzumabNaive NK Cell + obinutuzumabGCC4001 + Gazyva
02
Targets
Beyond the preview
Go deeper on GCC4001 + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCC4001 + obinutuzumab.